Evidence map›Paper›PMID 30968158›Full record

ArticleInternational journal of oncology2019

FABP5 regulates the proliferation of clear cell renal cell carcinoma cells via the PI3K/AKT signaling pathway.

Qi Lv, Gangmin Wang, Yinan Zhang, Xiao Han, Haoming Li, Wei Le, Minguang Zhang, Chunhui Ma, Peijun Wang, Qiang Ding

Open access · hybridAbstract read
In one paragraph

Article in International journal of oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Lipid metabolism reprogramming in renal cell carcinomas.Medical oncology (Northwood, London, England) · 2024
    Review
  13. Article
  14. Article
  15. Article
  16. Plasma proteome fingerprint in kidney diseases.Frontiers in molecular biosciences · 2024
    Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

Qi Lv *Imaging Department of Tongji Hospital, Medical School of Tongji University, Shanghai 200065, P.R. China.
Gangmin Wang *Department of Urology, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China.
Yinan ZhangDepartment of Urology, Shandong Province affiliated Hospital, Shandong University, Jinan, Shandong 250021, P.R. China.
Xiao HanDepartment of Human Anatomy, Medical School of Nantong University, Nantong, Jiangsu 226001, P.R. China.
Haoming LiDepartment of Human Anatomy, Medical School of Nantong University, Nantong, Jiangsu 226001, P.R. China.
Wei LeImaging Department of Tongji Hospital, Medical School of Tongji University, Shanghai 200065, P.R. China.
Minguang ZhangDepartment of Urology, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China.
Chunhui MaDepartment of Orthopedic Surgery, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai 200080, P.R. China.
Peijun WangImaging Department of Tongji Hospital, Medical School of Tongji University, Shanghai 200065, P.R. China.
Qiang DingDepartment of Urology, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China.
Fudan University · CNNantong University · CNTongji University · CNHuashan Hospital · CNShandong University · CNShanghai First People's Hospital · CNTongji Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC) has been associated with one of the highest mortality rates among all cancers. Fatty acid binding proteins (FABPs) are 14‑15 kDa proteins that are highly abundant in the cytosol of most tissues. FABP5, a member of the FABP family, has been observed to promote tumor cell growth in numerous cancer types. In order to investigate the function of FABP5 in ccRCC cells in the present study, RNA sequencing data from The Cancer Genome Atlas were analyzed to determine the expression levels of FABP5 in ccRCC patient samples. Survival and Cox regression analyses were performed to measure the association between FABP5 expression and clinicopathological features of patients with ccRCC. Subsequent in vitro experiments downregulated or overexpressed FABP5 in Caki‑1 and 786O ccRCC cells using lentiviral vectors to evaluate cell proliferation ability, and a xenograft transplantation model was established to examine the effect of FABP5 on tumorigenesis in vivo. The results demonstrated that FABP5 expression was significantly upregulated in samples from patients with ccRCC when compared with normal tissue samples. High FABP5 expression was also significantly correlated with tumor and metastasis classifications and predicted poor survival in patients with ccRCC. In ccRCC cells, silencing of FABP5 significantly inhibited cell proliferation, while overexpression of FABP5 promoted cell proliferation when compared to the respective controls. In addition, treatment with the phosphatidylinositol‑4,5‑bisphosphate 3‑kinase (PI3K)/AKT inhibitor, LY294002, attenuated the pro‑proliferative effects of exogenous FABP5 expression in Caki‑1 and 786O cells. This indicated that the PI3K/AKT signaling pathway may be partially involved in the FABP5‑mediated increase in ccRCC cell proliferation. Furthermore, FABP5 was observed to regulate tumor growth in nude mice in vivo. In conclusion, the results of the present study suggest that FABP5 may exert a pro‑proliferative role in ccRCC and may be associated with malignant progression and tumorigenesis.

Indexed as

AnimalsCarcinoma, Renal CellCell Line, TumorCell ProliferationChromonesComputational BiologyFatty Acid-Binding ProteinsFemaleHumansKidney NeoplasmsMaleMice, NudeMiddle AgedMorpholinesPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase Inhibitors2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-oneChromonesFABP5 protein, humanFatty Acid-Binding ProteinsMorpholinesPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsProto-Oncogene Proteins c-aktclear cell renal cell carcinomafatty acid binding protein 5phosphatidylinositol-4,5-bisphosphate 3-kinase/AKT signaling pathwayproliferation

Identifiers

PMID30968158
PMCPMC6411348
OpenAlexW2915987915

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.